

ZYDUS PHARMACEUTICALS CANADA INC [CANADA]			
Balance Sheet as at March 31, 2025			
Particulars	Note No.	CAD (in Thousand)	
		As at March 31	
		2025	2024
ASSETS:			
CURRENT			
Cash and Cash Equivalents	3	422	-
Prepaid Expenses		50	-
Government Receivable		7	-
		479	-
NON-CURRENT			
Property and Equipment	4	562	2
Deferred Tax Assets [Net]	12	466	27
		1,028	29
Total		1,507	29
LIABILITIES AND SHAREHOLDER'S EQUITY			
CURRENT			
Current portion of Obligation under Lease	13	95	-
Accounts Payable and other liabilities	5	174	103
		269	103
NON-CURRENT			
Borrowings	6	862	-
Obligation under Lease	13	347	-
		1,209	-
Shareholder's Equity			
Share Capital	7	1,350	-
Retained Earnings		(1,321)	(74)
		29	(74)
Total		1,507	29
For and on behalf of the Board			
sd/-			
Director			
Dated : April 30, 2025			
ZYDUS PHARMACEUTICALS CANADA INC [CANADA]			
Statement of Profit and Loss for the year ended March 31, 2025			
Particulars	Note No.	CAD (in Thousand)	
		Year ended March 31	
		2025	2024
Total Income		-	-
EXPENSES:			
Selling, General and administrative	8	102	-
Employee Cost	9	1,184	29
Interest and Bank Charges	10	17	-
Amortization	4	57	-
Other Expenses	11	302	72
Foreign Exchange Loss		24	-
		1,686	101
Loss before Income Taxes		(1,686)	(101)
INCOME TAXES			
Deferred Tax	13	(439)	(27)
		(439)	(27)
Net Loss after Taxes		(1,247)	(74)
Retained Earnings - Beginning of the year		(74)	-
Retained Earnings - End of the year		(1,321)	(74)
For and on behalf of the Board			
Sd/-			
Director			
Dated : April 30, 2025			

ZYDUS PHARMACEUTICALS CANADA INC [CANADA]
Cash Flow Statement for the year ended March 31, 2025

Particulars	CAD (in Thousand)	
	Year ended March 31	
	2025	2024
A Cash flows from operating activities:		
Net Loss after Taxes	(1,247)	(74)
Items not affecting cash:		
Amortisation	57	-
Future income Taxes	(439)	(27)
Foreign Exchange Loss (unrealised)	20	-
Interest expense	13	-
Total	(349)	(27)
Changes in non-cash working capital balances related to operations:	(1,596)	(101)
Prepaid Expenses	(50)	-
Government receivables	(7)	-
Accounts Payable and accrued liabilities	61	103
Lease Liability	442	-
Total	446	103
Cash generated from operations	(1,150)	2
Cash flow provided by (used in) operating activities	(1,150)	2
B Cash flows from investing activities:		
Purchase of property and equipment	(617)	(2)
Cash flow provided by (used in) investing activities	(617)	(2)
C Cash flows from financing activities:		
Proceeds from Issue of Common Share	1,350	-
Proceeds from non current borrowings	842	-
Interest paid	(3)	-
Cash flow provided by (used in) financing activities	2,189	-
Increase/ [Decrease] in cash	422	-
Cash and Cash Equivalents - BEGINNING OF THE YEAR	-	-
Cash Cash Equivalents - END OF THE YEAR	422	-

For and on behalf of the Board

sd/-

Director
Dated : April 30, 2025

ZYDUS PHARMACEUTICALS CANADA INC [CANADA]**Note: 1-Company overview:**

ZyduS Pharmaceuticals (Canada) Inc. ["the Company"] [Corporation number: 1533743-7], a Company unlimited by shares, incorporated and domiciled in Canada. The registered office of the Company is located at 2425 Matheson Blvd East, Suite 602, Mississauga ON Canada L4W 5K4.

Note: 2-Summary of Significant Accounting Policies:

These financial statements have been prepared in accordance with Canadian accounting standards for private enterprises and include the following significant accounting policies:

Cash and Cash Equivalents

Cash and Cash Equivalents includes balances with banks.

Revenue recognition

Revenue from the product sales is recognized when significant risk and rewards in respect to ownership of the products have been passed to the customer, and when the following criteria have been met:

- persuasive evidence of an arrangement exists;
- there are no significant obligations remaining;
- the price is fixed and determinable; and
- collectability is reasonably assured

Revenue from product sales is recognized net of provisions for estimated discounts, returns, rebates and chargebacks offered to wholesale customers.

Inventories

Inventories, comprising of finished goods, are measured at the lower of cost and net realizable value. Cost is determined on a moving average basis. The cost of inventories includes freight and any other directly attributable costs. Net realizable value is determined on the basis of estimated selling prices, less costs necessary to make the sale. When circumstances which previously caused inventories to be written down below cost no longer exist, the previous impairment is reversed.

Property and equipment

Property and equipment are stated at cost less accumulated amortization. Property and equipment, other than land, are amortized over their estimated useful lives using the following rates and methods:

Leasehold improvements Straight line over the term of the lease

Furniture and Fixtures is depreciated over the period of 7 years using Straight line

Computer equipment is depreciated over the period of 3 years using Straight line

Office equipment is depreciated over the period of 3 years using Straight line

Income taxes

The Company accounts for income taxes using the future income taxes method. Under this method, Deferred tax assets and liabilities are recorded based on temporary differences between the carrying amount of balance sheet items and their corresponding tax bases. In addition, the future benefits of income tax assets, including unused tax losses, are recognized, subject to a valuation allowance, to the extent that it is more likely than not that such future benefits will ultimately be realized. Deferred tax assets and liabilities are measured using substantively enacted tax rates and laws expected to apply when the tax liabilities or assets are to be either settled or realized.

Foreign currency translation

These financial statements have been presented in Canadian dollars, the Company's functional currency. Transaction amounts denominated in foreign currencies are translated into their Canadian dollar equivalents at exchange rates prevailing at the transaction dates. Carrying values of monetary assets and liabilities, which are denominated in foreign currencies, reflect the exchange rates at the balance sheet date. Gains and losses resulting from currency translation are included in the statement of operations.

Use of estimates

The preparation of financial statements in conformity with Canadian accounting standards for private enterprises requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the year. These estimates and assumptions are reviewed periodically, which include allowance for doubtful accounts, provisions for inventory obsolescence, valuation allowance for future tax benefits, impairment of financial assets, and accruals, and as adjustments become necessary, they are reported in net income in the year in which they become known. Actual results may vary from the current estimates.

Financial instruments

The Company initially measures all its financial assets and liabilities at fair value, except for certain related party transactions that are measured at the carrying amount or exchange amount, as appropriate.

The Company subsequently measures all its financial assets and financial liabilities at cost or amortized cost.

Financial assets measured at cost or amortized cost includes cash, accounts receivable and due from related company.

Financial liabilities measured at cost or amortized cost includes accounts payable and accrued liabilities.

Impairment of financial instruments

Financial assets measured at cost or amortized cost are tested for impairment when there are indicators of impairment. The amount of write-down is recognized in net income. A previously recognized impairment loss may be reversed to the extent of improvement, directly or by adjusting the allowance account, provided it is no greater than the amount that would have been reported at the date of the reversal had the impairment not been recognized previously. The amount of the reversal is recognized in statement of operations.

ZYDUS PHARMACEUTICALS CANADA INC [CANADA]					
Notes to the Financial Statements					
				CAD (in Thousand)	
				As at March 31	
				2025	2024
Note: 3-Cash and Cash Equivalents:					
A Bank Balance:					
Balances with Banks				422	-
Total				422	-
Note: 4-Property and Equipment:					
	Leasehold Buildings & Improvement	Furniture and Fixtures	Office Equipment	Computer Equipment	Total
Gross Block:					
As at September 06, 2023	-	-	-	-	-
Additions	-	-	-	2	2
Disposals	-	-	-	-	-
As at March 31, 2024	-	-	-	2	2
Additions	575	23	14	5	617
Disposals	-	-	-	-	-
As at March 31, 2025	575	23	14	7	619
Depreciation and Impairment:					
As at September 06, 2023	-	-	-	-	-
Depreciation for the period	-	-	-	-	-
Impairment for period	-	-	-	-	-
Disposals	-	-	-	-	-
As at March 31, 2024	-	-	-	-	-
Depreciation for the year	51	2	2	2	57
Impairment for the year	-	-	-	-	-
Disposals	-	-	-	-	-
As at March 31, 2025	51	2	2	2	57
Net Block:					
As at March 31, 2024	-	-	-	2	2
As at March 31, 2025	524	21	12	5	562
				CAD (in Thousand)	
				As at March 31	
				2025	2024
Note: 5-Accounts Payable and Other Liabilities:					
Accounts Payable				96	-
Interest accrued but not due on borrowings				10	-
Accrued Expenses				68	103
Payable to Government (in 2025: CAD 196)				-	-
Total				174	103
Note: 6-Borrowings:					
CAD (in Thousand)					
		Non-current portion		Current Maturities	
		As at March 31		As at March 31	
		2025	2024	2025	2024
A From Related Parties [Unsecured]		862	-	-	-
Total		862	-	-	-
The above amount includes:					
Secured borrowings		-	-	-	-
Unsecured borrowings		862	-	-	-
Net amount		862	-	-	-
Terms of Repayment of Unsecured Borrowings					
The company has borrowed funds from one of the fellow subsidiary company and it will be repaid within 2 years and can be rolled over for one more year. Interest on Loan is repayable on quarterly basis.					
The interest rates on the above loans is 3M USD SOFAR plus a margin of 0.50bps.					
Note: 7-Share Capital:					
Issued:					
563,657 Common Shares				1,350	-
				1,350	-

ZYDUS PHARMACEUTICALS CANADA INC [CANADA]		
Notes to the Financial Statements		
	CAD (in Thousand)	
	Year ended March 31	
	2025	2024
Note: 8-Selling General and Administrative:		
Other marketing expenses	102	-
Total	102	-
Note: 9-Employee Benefits Expense:		
Salaries and wages	1,157	29
Contribution to Pension Plan and Other Funds	26	-
Staff welfare expenses	1	-
Total	1,184	29
Note: 10-Finance Cost:		
Interest expense - intercompany Working Capital Loan [*]	13	-
Bank commission & charges	4	-
Total	17	-
Note: 11-Other Expenses:		
Rent	21	-
Insurance	16	-
Traveling Expenses	100	-
Legal and Professional Fees	-	64
Miscellaneous Expenses	165	8
Total	302	72
Note: 12-Deferred Tax:		
Deferred Tax - Non-current		
Difference between tax basis over carrying value of property and equipment	19	14
Non-capital losses carried forward	447	13
	466	27
Note: 13-Leases:		
	CAD (in Thousand)	
	As at March 31	
	2025	2024
Building has lease bearing interest at 5.63% per annum and maturing in September 2029.	442	-
Current portion	(95)	-
	347	-
Future minimum lease payments required are as follows		
2026	117	-
2027	118	-
2028	120	-
2029	120	-
2030	20	-
	495	-
Interest included in minimum payments	(53)	-
	442	-

ZYDUS PHARMACEUTICALS CANADA INC [CANADA]				
Notes to the Financial Statements				
Note: 14-Related Party Transactions:				
A Name of the Related Parties and Nature of the Related Party Relationship:				
a Holding Company:		Zydus Lifesciences Limited		
b Fellow subsidiary Companies/concerns with whom transactions done during the period:		Zydus Pharmaceuticals (USA) Inc. [USA] Viona Pharmaceuticals Inc. [USA]		
c Key Managerial Personnel:				
Puja Shah Chunnoo		Director (resigned w.e.f 05/15/2025)		
Rajeev Lamba		Director		
Ravi Yadavar		Director		
Vinod Ramachandran		Director (appointed w.e.f 05/20/2024)		
B Transactions with Related Parties:				
The following transactions were carried out with the related parties in the ordinary course of business and at arm's length terms:				
a Details relating to parties referred to in Note 14-A [a, b]				
		Value of the Transactions [CAD] [in Thousand]		
	Holding Company	Subsidiary/ Fellow subsidiary Companies		
		Year ended March 31		
<u>Nature of Transactions</u>	2025	2024	2025	2024
Reimbursement of Expenses paid:				
Zydus Pharmaceuticals (USA) Inc. [USA]	-	-	7	-
Viona Pharmaceuticals Inc. [USA]	-	-	4	4
Purchases:				
Property, Plant and Equipment:				
Zydus Pharmaceuticals (USA) Inc. [USA]	-	-	-	2
Finance:				
Inter Corporate Loans accepted				
Zydus Pharmaceuticals (USA) Inc. [USA]	-	-	843	-
Interest Expense				
Zydus Pharmaceuticals (USA) Inc. [USA]	-	-	13	-
Issue of Shares				
Zydus Lifesciences Limited	1,350	-	-	-
	2025	2024	2025	2024
Outstanding Payable				
Zydus Pharmaceuticals (USA) Inc. [USA]	-	-	872	-
Viona Pharmaceuticals Inc. [USA]	-	-	-	-
Note: 15-Financial Instruments:				
The Company is exposed to various risks through its financial instruments. The following analysis provides a measure of the Company's risk exposure and concentrations at the balance sheet date, March 31, 2025, which did not change significantly from the previous period unless otherwise noted.				
Credit risk				
Credit risk is the risk that a counter party will fail to perform its obligations. The Company's main credit risks relate to its cash and bank balances. The Company manages the credit risk from its cash balances by maintaining its accounts with credit worthy and highly reputable financial institutions.				
Currency risk				
Currency risk is the risk that the fair value or future cash flows of a financial liability will fluctuate because of changes in foreign exchange rates. The expenditure incurred in United States Dollars (USD) for which the related expense and accounts payable balances are subject to exchange rate fluctuations. The Company does not use derivative instruments to reduce its exposure to foreign currency risk.				
Accounts payable and Borrowings held in United States dollars as at year ended are as follows:				
			USD (in Thousand)	
			As at March 31	
			2025	2024
Accounts payable			7	-
Interest accrued but not due on borrowings			7	-
Borrowings			600	-
Liquidity risk				
Liquidity risk is the risk that an entity will encounter difficulty in meeting obligations associated with financial liabilities. The Company is exposed to this risk mainly in respect of its accounts payable. The Company manages liquidity risk by maintaining sufficient cash on hand to settle obligations as they arise. Further, the Ultimate Parent continues to provide support to the Company, as and when required.				
Interest rate risk				
Interest rate risk is the risk that the value of a financial instrument might be adversely affected by a change in the interest rates. In seeking to minimize the risks from interest rate fluctuations, the Company manages exposure through its normal operating and financing activities. The Company is exposed to interest rate risk on its Borrowings.				
Note: 16-Comparative Figures:				
Figures of previous year have been regrouped / reclassified to conform to current year's classification.				
For and on behalf of the Board				
sd/-				
Director				
Dated : April 30, 2025				